Story perspectives

Merck Surpasses Q1 Earnings Expectations Despite Sales Dip

4/24/2025

39 5

Summary

Story summary

Merck & Co. reported Q1 2025 adjusted earnings of $2.22 per share, surpassing expectations despite a 2% sales decline to $15.5 billion.
Keytruda sales increased by 4% to $7.2 billion, while Gardasil sales dropped 41% due to low demand in China.
The company revised its 2025 adjusted earnings guidance to $8.82-$8.97 per share, factoring in $200 million in tariff costs.
Merck continues to project full-year sales between $64.1 billion and $65.6 billion.

History

Historical Context

Merck's Q1 2025 earnings reveal ongoing challenges in the pharmaceutical market, reminiscent of the 2006 introduction of Gardasil. Initially met with skepticism, Gardasil's eventual success in reducing cervical cancer rates parallels Merck's current efforts to adapt amidst fluctuating sales and rising costs, particularly in China.

1 of 2

Story summary

Merck & Co. reported Q1 2025 adjusted earnings of $2.22 per share, surpassing expectations despite a 2% sales decline to $15.5 billion.
Keytruda sales increased by 4% to $7.2 billion, while Gardasil sales dropped 41% due to low demand in China.
The company revised its 2025 adjusted earnings guidance to $8.82-$8.97 per share, factoring in $200 million in tariff costs.
Merck continues to project full-year sales between $64.1 billion and $65.6 billion.

1 / 2